Statistical Implications of the CGMPs: A 30-Year Retrospective - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Statistical Implications of the CGMPs: A 30-Year Retrospective
This article looks at the current good manufacturing practice regulations from a statistical perspective while addressing their requirements and implications and inviting the industry to assess its past performance in meeting the regulations.


Pharmaceutical Technology


The director of quality control walked up to my cubicle at G.D. Searle in Skokie, Illinois, and said, "FDA has just published a revision to the Current Good Manufacturing Practice regulations, and I would like for you to review it for the statistical implications." It was February 1976, I had been with the company less than two months, and so started my 30-year career of applied statistics in the service of the current good manufacturing practice (CGMP) regulations. That internal memo later became a formal presentation at the 20th annual Quality Clinic (1) and I have primarily pursued the same goal ever since.

The 30th anniversary issue of Pharmaceutical Technology now prompts the same question and a related question: How have we, the pharmaceutical industry, done in responding to the statistical implications?

The first set of regulations for finished pharmaceuticals was published in 1963 by the Food and Drug Administration, (FDA) on the basis of standards developed by the industry and by the Pharmaceutical Manufacturers Association in 1961. These regulations were amended in 1965, revised in 1971, amended again February 13, 1976 (2), and published in the Federal Register as 21 CFR 210 and 211.

Sampling

A reading of 21 CFR 210 and 211 finds statistical topics expressed both explicitly and implicitly. The most frequently occurring topics are representative samples, sampling, and sampling plans. Section 210 (20) finds

Acceptance criteria means the product specifications and acceptance/rejection criteria, such as acceptable quality level and unacceptable quality level, with associated sampling plan, that are necessary for making a decision to accept or reject a lot or batch.



Note that there are three parts to the acceptance criteria: the specifications, the acceptable quality level (AQL) (3), and the unacceptable quality level. The unacceptable quality level is usually known as the limiting quality (LQ). (Note that the definition of AQL changed in the 2003 version of ANSI/ASQ Z1.4 to be the acceptable quality limit.) The acceptable quality limit (AQL) is the percent of defects or defectives that is the worst tolerable process average. The probability of rejection at the AQL is the "producer's risk." A typical sampling plan will reject 5% or less of the lots with a defect level at or less than the AQL. The LQ is the percent of defects or defectives that is unacceptable. The probability of acceptance is the "consumer's risk." A typical sampling plan will accept 5% (or 10%) or more of the lots with this defect level or greater. The implication is that we should look for all three parts anywhere the term acceptance criteria appears. Most standard operating procedures and manufacturing instructions give the specifications and the AQL, but few provide the LQ. Historically, sampling plans were indexed primarily by the AQL with little note of the LQ values. With FDA's new emphasis on risk and risk management, however, the LQ or consumer's risk takes on new importance for compliance.

Manufacturers typically interpret the regulations to mean that they must set their internal product specifications requirements tighter than the regulatory compendial requirements. As stated in USP, "Confusion of compendial standards with release tests and with statistical sampling plans occasionally occurs" (4). Compendial standards define what constitutes an acceptable article and describe test procedures that demonstrate that the article is in compliance. These standards apply at any time in the life of the article from production to consumption. The manufacture's release specifications, and compliance with good manufacturing practices generally, are developed and followed to ensure the article will indeed comply with compendial standards until its expiration date, when stored as directed.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here